Pharmacology
Tasidotin hydrochloride was evaluated in patients with advanced solid tumors
Published in Cancer Weekly, November 14th, 2006
Researchers in the United States conducted a study "to determine the safety, tolerability, and pharmacokinetics and to seek preliminary evidence of anticancer activity of tasidotin, a novel dolastatin analogue, when administered as a 30-minute i.v. infusion weekly for 3 weeks every 4 weeks. Thirty patients with advanced solid malignancies were treated with 82 courses at 6 dose levels ranging from 7.8 to 62.2 mg/m2 weekly, initially according to an accelerated dose-escalation scheme, which evolved into a Fibonacci scheme as a relevant...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2006-11-14)
More Articles from Cancer Weekly
- Apoptosis
Ewing sarcoma cell apoptosis induced by arsenic trioxide - Breast Cancer
Breast cancer treated by butyroyloxymethyl-diethyl phosphate and doxorubicin - Diet & Nutrition
Benign prostatic hyperplasia risk reduced with intake of selected micronutrients - Diet & Nutrition
Cancer survival might depend on season of diagnosis and sunlight exposure - Drug Development
Randomized approaches might decrease high failure rate for oncological drugs in phase III trials - Cancer Gene Therapy
Dankook University, Institute of Nanosensor and Biotechnology details research in cancer gene therapy - More from this issue of Cancer Weekly
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
